Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society

J. A. French, Andres M Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, D. Bergen, D. Hirtz, G. D. Montouris, M. Nespeca, B. Gidal, W. J. Marks, W. R. Turk, J. R. Fischer, B. Bourgeois, A. WilnerR. E. Faught, R. C. Sachdeo, A. Beydoun, T. A. Glauser

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide - reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalCONTINUUM Lifelong Learning in Neurology
Volume13
Issue number4 EPILEPSY
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Biomedical Technology Assessment
Anticonvulsants
Generalized Epilepsy
Epilepsy
zonisamide
etiracetam
Committee Membership
Absence Epilepsy
Partial Epilepsy
Prescription Drugs
United States Food and Drug Administration
MEDLINE
Libraries
Seizures
Therapeutics
Guidelines
Pediatrics
Safety
lamotrigine
oxcarbazepine

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Appendix C : Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. / French, J. A.; Kanner, Andres M; Bautista, J.; Abou-Khalil, B.; Browne, T.; Harden, C. L.; Theodore, W. H.; Bazil, C.; Stern, J.; Schachter, S. C.; Bergen, D.; Hirtz, D.; Montouris, G. D.; Nespeca, M.; Gidal, B.; Marks, W. J.; Turk, W. R.; Fischer, J. R.; Bourgeois, B.; Wilner, A.; Faught, R. E.; Sachdeo, R. C.; Beydoun, A.; Glauser, T. A.

In: CONTINUUM Lifelong Learning in Neurology, Vol. 13, No. 4 EPILEPSY, 08.2007, p. 203-211.

Research output: Contribution to journalArticle

French, JA, Kanner, AM, Bautista, J, Abou-Khalil, B, Browne, T, Harden, CL, Theodore, WH, Bazil, C, Stern, J, Schachter, SC, Bergen, D, Hirtz, D, Montouris, GD, Nespeca, M, Gidal, B, Marks, WJ, Turk, WR, Fischer, JR, Bourgeois, B, Wilner, A, Faught, RE, Sachdeo, RC, Beydoun, A & Glauser, TA 2007, 'Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society', CONTINUUM Lifelong Learning in Neurology, vol. 13, no. 4 EPILEPSY, pp. 203-211. https://doi.org/10.1212/01.CON.0000284529.35649.1d
French, J. A. ; Kanner, Andres M ; Bautista, J. ; Abou-Khalil, B. ; Browne, T. ; Harden, C. L. ; Theodore, W. H. ; Bazil, C. ; Stern, J. ; Schachter, S. C. ; Bergen, D. ; Hirtz, D. ; Montouris, G. D. ; Nespeca, M. ; Gidal, B. ; Marks, W. J. ; Turk, W. R. ; Fischer, J. R. ; Bourgeois, B. ; Wilner, A. ; Faught, R. E. ; Sachdeo, R. C. ; Beydoun, A. ; Glauser, T. A. / Appendix C : Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. In: CONTINUUM Lifelong Learning in Neurology. 2007 ; Vol. 13, No. 4 EPILEPSY. pp. 203-211.
@article{fd81a522a3524987b778cdfe4fa97342,
title = "Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society",
abstract = "Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide - reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.",
author = "French, {J. A.} and Kanner, {Andres M} and J. Bautista and B. Abou-Khalil and T. Browne and Harden, {C. L.} and Theodore, {W. H.} and C. Bazil and J. Stern and Schachter, {S. C.} and D. Bergen and D. Hirtz and Montouris, {G. D.} and M. Nespeca and B. Gidal and Marks, {W. J.} and Turk, {W. R.} and Fischer, {J. R.} and B. Bourgeois and A. Wilner and Faught, {R. E.} and Sachdeo, {R. C.} and A. Beydoun and Glauser, {T. A.}",
year = "2007",
month = "8",
doi = "10.1212/01.CON.0000284529.35649.1d",
language = "English (US)",
volume = "13",
pages = "203--211",
journal = "CONTINUUM Lifelong Learning in Neurology",
issn = "1080-2371",
publisher = "Lippincott Williams and Wilkins",
number = "4 EPILEPSY",

}

TY - JOUR

T1 - Appendix C

T2 - Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society

AU - French, J. A.

AU - Kanner, Andres M

AU - Bautista, J.

AU - Abou-Khalil, B.

AU - Browne, T.

AU - Harden, C. L.

AU - Theodore, W. H.

AU - Bazil, C.

AU - Stern, J.

AU - Schachter, S. C.

AU - Bergen, D.

AU - Hirtz, D.

AU - Montouris, G. D.

AU - Nespeca, M.

AU - Gidal, B.

AU - Marks, W. J.

AU - Turk, W. R.

AU - Fischer, J. R.

AU - Bourgeois, B.

AU - Wilner, A.

AU - Faught, R. E.

AU - Sachdeo, R. C.

AU - Beydoun, A.

AU - Glauser, T. A.

PY - 2007/8

Y1 - 2007/8

N2 - Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide - reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.

AB - Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide - reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.

UR - http://www.scopus.com/inward/record.url?scp=34548384768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548384768&partnerID=8YFLogxK

U2 - 10.1212/01.CON.0000284529.35649.1d

DO - 10.1212/01.CON.0000284529.35649.1d

M3 - Article

AN - SCOPUS:34548384768

VL - 13

SP - 203

EP - 211

JO - CONTINUUM Lifelong Learning in Neurology

JF - CONTINUUM Lifelong Learning in Neurology

SN - 1080-2371

IS - 4 EPILEPSY

ER -